Prolongation of the QT interval induced by probucol: Demonstration of a method for determining QT interval change induced by a drug

Kevin F. Browne, Eric N. Prystowsky, James J. Heger, Benjamin J. Cerimele, Naomi Fineberg, Douglas P. Zipes

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Sudden death has occurred in monkeys fed large doses of probucol, a cholesterol-lowering drug, given in combination with an atherogenic diet. These monkeys develop prolonged QT intervals and high serum levels of probucol. We investigated the effect of probucol on QT interval and the incidence of ventricular ectopy during a double-blind placebo-controlled study in 16 patients with less than 600 premature ventricular complexes (PVCs) per day and a corrected QT interval of less than 0.44 second. Seven patients received probucol and nine patients received placebo. Three 24-hour continuous ECG recordings were obtained prior to entry into the study and three additional recordings were obtained after 6 months of drug or placebo therapy. A 15-second ECG tracing was sampled from the continuous ECG recording every 30 minutes and, for the group, 15,000 QT intervals were measured permitting construction of QT versus R-R regression lines for each patient before and during therapy. Comparison of the regression lines revealed that the measured QT interval prolonged 20 ± 18 msec during the awake state and 24 ± 20 msec during sleep (mean + standard deviation) at matched heart rates in the seven patients receiving probucol (p < 0.01). Using Bazett's formula to correct for rate, corrected QT interval prolonged 22 ± 23 msec in the awake state and 20 ± 18 msec in the asleep state (p < 0.01). In probucol treated patients QT interval prolongation was directly related to increasing probucol plasma levels (p < 0.05). PVCs did not increase in either group. In summary, probucol prolongs QT interval in humans but does not increase the number of PVCs in patients with normal QT intervals prior to probucol treatment. Although the magnitude of QT prolongation in these patients is small, monitoring of the QT interval while administering probucol may be indicated in some patients.

Original languageEnglish (US)
Pages (from-to)680-684
Number of pages5
JournalAmerican Heart Journal
Volume107
Issue number4
DOIs
StatePublished - Apr 1984

Fingerprint

Probucol
Pharmaceutical Preparations
Ventricular Premature Complexes
Electrocardiography
Placebos
Haplorhini
Atherogenic Diet
Sudden Death
Sleep
Therapeutics
Heart Rate
Cholesterol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prolongation of the QT interval induced by probucol : Demonstration of a method for determining QT interval change induced by a drug. / Browne, Kevin F.; Prystowsky, Eric N.; Heger, James J.; Cerimele, Benjamin J.; Fineberg, Naomi; Zipes, Douglas P.

In: American Heart Journal, Vol. 107, No. 4, 04.1984, p. 680-684.

Research output: Contribution to journalArticle

Browne, Kevin F. ; Prystowsky, Eric N. ; Heger, James J. ; Cerimele, Benjamin J. ; Fineberg, Naomi ; Zipes, Douglas P. / Prolongation of the QT interval induced by probucol : Demonstration of a method for determining QT interval change induced by a drug. In: American Heart Journal. 1984 ; Vol. 107, No. 4. pp. 680-684.
@article{5b4274de5d024ea185ec209ac52ef5d3,
title = "Prolongation of the QT interval induced by probucol: Demonstration of a method for determining QT interval change induced by a drug",
abstract = "Sudden death has occurred in monkeys fed large doses of probucol, a cholesterol-lowering drug, given in combination with an atherogenic diet. These monkeys develop prolonged QT intervals and high serum levels of probucol. We investigated the effect of probucol on QT interval and the incidence of ventricular ectopy during a double-blind placebo-controlled study in 16 patients with less than 600 premature ventricular complexes (PVCs) per day and a corrected QT interval of less than 0.44 second. Seven patients received probucol and nine patients received placebo. Three 24-hour continuous ECG recordings were obtained prior to entry into the study and three additional recordings were obtained after 6 months of drug or placebo therapy. A 15-second ECG tracing was sampled from the continuous ECG recording every 30 minutes and, for the group, 15,000 QT intervals were measured permitting construction of QT versus R-R regression lines for each patient before and during therapy. Comparison of the regression lines revealed that the measured QT interval prolonged 20 ± 18 msec during the awake state and 24 ± 20 msec during sleep (mean + standard deviation) at matched heart rates in the seven patients receiving probucol (p < 0.01). Using Bazett's formula to correct for rate, corrected QT interval prolonged 22 ± 23 msec in the awake state and 20 ± 18 msec in the asleep state (p < 0.01). In probucol treated patients QT interval prolongation was directly related to increasing probucol plasma levels (p < 0.05). PVCs did not increase in either group. In summary, probucol prolongs QT interval in humans but does not increase the number of PVCs in patients with normal QT intervals prior to probucol treatment. Although the magnitude of QT prolongation in these patients is small, monitoring of the QT interval while administering probucol may be indicated in some patients.",
author = "Browne, {Kevin F.} and Prystowsky, {Eric N.} and Heger, {James J.} and Cerimele, {Benjamin J.} and Naomi Fineberg and Zipes, {Douglas P.}",
year = "1984",
month = "4",
doi = "10.1016/0002-8703(84)90315-6",
language = "English (US)",
volume = "107",
pages = "680--684",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Prolongation of the QT interval induced by probucol

T2 - Demonstration of a method for determining QT interval change induced by a drug

AU - Browne, Kevin F.

AU - Prystowsky, Eric N.

AU - Heger, James J.

AU - Cerimele, Benjamin J.

AU - Fineberg, Naomi

AU - Zipes, Douglas P.

PY - 1984/4

Y1 - 1984/4

N2 - Sudden death has occurred in monkeys fed large doses of probucol, a cholesterol-lowering drug, given in combination with an atherogenic diet. These monkeys develop prolonged QT intervals and high serum levels of probucol. We investigated the effect of probucol on QT interval and the incidence of ventricular ectopy during a double-blind placebo-controlled study in 16 patients with less than 600 premature ventricular complexes (PVCs) per day and a corrected QT interval of less than 0.44 second. Seven patients received probucol and nine patients received placebo. Three 24-hour continuous ECG recordings were obtained prior to entry into the study and three additional recordings were obtained after 6 months of drug or placebo therapy. A 15-second ECG tracing was sampled from the continuous ECG recording every 30 minutes and, for the group, 15,000 QT intervals were measured permitting construction of QT versus R-R regression lines for each patient before and during therapy. Comparison of the regression lines revealed that the measured QT interval prolonged 20 ± 18 msec during the awake state and 24 ± 20 msec during sleep (mean + standard deviation) at matched heart rates in the seven patients receiving probucol (p < 0.01). Using Bazett's formula to correct for rate, corrected QT interval prolonged 22 ± 23 msec in the awake state and 20 ± 18 msec in the asleep state (p < 0.01). In probucol treated patients QT interval prolongation was directly related to increasing probucol plasma levels (p < 0.05). PVCs did not increase in either group. In summary, probucol prolongs QT interval in humans but does not increase the number of PVCs in patients with normal QT intervals prior to probucol treatment. Although the magnitude of QT prolongation in these patients is small, monitoring of the QT interval while administering probucol may be indicated in some patients.

AB - Sudden death has occurred in monkeys fed large doses of probucol, a cholesterol-lowering drug, given in combination with an atherogenic diet. These monkeys develop prolonged QT intervals and high serum levels of probucol. We investigated the effect of probucol on QT interval and the incidence of ventricular ectopy during a double-blind placebo-controlled study in 16 patients with less than 600 premature ventricular complexes (PVCs) per day and a corrected QT interval of less than 0.44 second. Seven patients received probucol and nine patients received placebo. Three 24-hour continuous ECG recordings were obtained prior to entry into the study and three additional recordings were obtained after 6 months of drug or placebo therapy. A 15-second ECG tracing was sampled from the continuous ECG recording every 30 minutes and, for the group, 15,000 QT intervals were measured permitting construction of QT versus R-R regression lines for each patient before and during therapy. Comparison of the regression lines revealed that the measured QT interval prolonged 20 ± 18 msec during the awake state and 24 ± 20 msec during sleep (mean + standard deviation) at matched heart rates in the seven patients receiving probucol (p < 0.01). Using Bazett's formula to correct for rate, corrected QT interval prolonged 22 ± 23 msec in the awake state and 20 ± 18 msec in the asleep state (p < 0.01). In probucol treated patients QT interval prolongation was directly related to increasing probucol plasma levels (p < 0.05). PVCs did not increase in either group. In summary, probucol prolongs QT interval in humans but does not increase the number of PVCs in patients with normal QT intervals prior to probucol treatment. Although the magnitude of QT prolongation in these patients is small, monitoring of the QT interval while administering probucol may be indicated in some patients.

UR - http://www.scopus.com/inward/record.url?scp=0021364249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021364249&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(84)90315-6

DO - 10.1016/0002-8703(84)90315-6

M3 - Article

C2 - 6702562

AN - SCOPUS:0021364249

VL - 107

SP - 680

EP - 684

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -